GINKGO BIOWORKS HOLDINGS, INC.
| Revenue | $132.4M |
|---|---|
| Operating income | $-129.9M |
| Net income | $-129.3M |
| Free cash flow | $-95.5M |
| Operating margin | -98.1% |
| Net margin | -97.6% |
| Return on equity | -30.8% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Strategic upside is plausible, but the call did not establish near-term financial accretion or reduce execution risk.
Hold: Ginkgo announced an $83 million Bayer West Sacramento asset purchase and an all-stock Zymergen acquisition valued at approximately $300 million, issuing Zymergen holders 5.25% of pro forma Ginkgo. The strategic logic—Bayer adds a major, multi-year customer collaboration while Zymergen adds automation and software—is credible, but management provided no quantified synergies, no Zymergen revenue contribution, and deferred Q2 performance and current-year guidance to the mid-August earnings call.
- Zymergen Acquisition
- Bayer Collaboration
- Foundry Automation
- M And A Strategy
- Integration Risk
- Cash Runway
Near term
Mid-August Q2 results and current-year guidance are the key near-term catalyst after management declined to provide a flash update.
Zymergen is expected to close by Q1 2023, subject to S-4 review, shareholder approval, regulatory clearance, and real-estate and litigation conditions.
Bayer collaboration revenue and the pace of cost reductions should determine whether the $83 million asset purchase is financially de-risked in the near term.
Longer term
Zymergen’s automation, software, data, and biological assets could improve Foundry throughput and unit economics; management cited an approximate 70% Foundry/automation weighting for the acquired technology value.
Bayer provides a multi-year commercial relationship and royalty upside from nitrogen-fixation products, but the specific commitment and economics were not disclosed.
The platform thesis depends on Ginkgo converting lower unit costs into more customer programs and downstream value share rather than merely absorbing additional infrastructure and personnel.
Competitive moat remains unproven: analysts pressed on whether Zymergen’s automation can integrate with Ginkgo’s systems and whether rack sales could cannibalize Foundry services, and management offered optionality rather than a quantified answer.
Red flags
Management explicitly said the Zymergen deal assumes no material revenue contribution; any revenue from advanced materials or drug-discovery spinouts is upside, not part of the business case.
Integration of two complex automation and software platforms, facility consolidation, employee retention, and back-office transition were not supported by quantified milestones or savings targets.
Zymergen carries long-term real-estate obligations, with potential adverse exposure if build-out costs exceed $25 million; subleasing and consolidation plans remain unfinished.
The company issued no Q2 update and reiterated that it only provides current-year guidance, leaving investors without a contemporaneous read on cash burn, customer demand, or the impact of the acquisitions.
Bayer is described as Ginkgo’s largest customer collaboration, but undisclosed commercial terms create concentration and underwriting risk.
Recommendation history
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-02-26
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 47.9%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -183.8%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -100.5%
- Cash Runway Low — Cash runway ~1.0 years
- Accumulated Deficit High — Accumulated deficit / equity 1209%
- Rd Intensity High — R&D/Revenue 143.3%